{"type":"trials","record":{"id":41457,"source_id":"clinicaltrials-gov","external_id":"NCT06683950","title":"Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment","brief_summary":"The treatment landscape for neovascular AMD has evolved with various anti-VEGF agents since 2006. Ranibizumab initially led the way, but its limited efficacy in reducing retinal edema paved the way for aflibercept in 2011, which became globally popular for its effectiveness and safety. Yet, aflibercept did not fully meet all patients' needs. In 2019, brolucizumab showed promising anatomical results but had higher risks of inflammation, limiting its use. Faricimab, introduced in 2022, aimed for longer-lasting effects by targeting VEGF-A and angiopoietin 2. Though it required fewer injections, questions remain about its long-term efficacy compared to aflibercept. Despite recent advancements, no agent has established itself as the new standard since aflibercept's introduction, leaving significant unmet needs. Aflibercept 8mg, approved in 2023, has shown promise by matching long-term visual outcomes of aflibercept 2mg with fewer injections and comparable safety. This study examines the effects of switching to aflibercept 8mg for patients with a limited response to previous treatments, addressing the potential for aflibercept 8mg to meet current needs more effectively and providing timely data for its global rollout.","overall_status":"Completed","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Kim's Eye Hospital","enrollment":35,"countries":["South Korea"],"start_date":"2024-10-21","completion_date":"2026-07-14","last_update_date":"2026-07-16","source_url":"https://clinicaltrials.gov/study/NCT06683950","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Kim's Eye Hospital","interventions":["Aflibercept 8mg"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Presence of retinal fluid — Between 8 - 16 weeks (At the same interval as the previous dosing schedule for aflibercept…","Change in best-corrected visual acuity (BCVA) — Between 8 - 16 weeks (At the same interval as the previous dosing sched…","Change in central retinal thickness (CRT) — Between 8 - 16 weeks (At the same interval as the previous dosing schedule…","Change in subfoveal choroidal thickness (SCT) — Between 8 - 16 weeks (At the same interval as the previous dosing sched…","Change in the size of neovascularization — Between 8 - 16 weeks (At the same interval as the previous dosing schedule f…","Maximum fluid-free period — Between 8 - 16 weeks (At the same interval as the previous dosing schedule for aflibercept…","The proportion of eyes exhibiting fluid — Between 8 - 16 weeks (At the same interval as the previous dosing schedule fo…"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Age-related Macular Degeneration (ARMD)","Aflibercept 8mg"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06683950","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-10-21 to 2026-07-14","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.816Z","intervention":["Aflibercept 8mg"],"participants":35,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Presence of retinal fluid — Between 8 - 16 weeks (At the same interval as the previous dosing schedule for aflibercept…","Change in best-corrected visual acuity (BCVA) — Between 8 - 16 weeks (At the same interval as the previous dosing sched…","Change in central retinal thickness (CRT) — Between 8 - 16 weeks (At the same interval as the previous dosing schedule…","Change in subfoveal choroidal thickness (SCT) — Between 8 - 16 weeks (At the same interval as the previous dosing sched…","Change in the size of neovascularization — Between 8 - 16 weeks (At the same interval as the previous dosing schedule f…","Maximum fluid-free period — Between 8 - 16 weeks (At the same interval as the previous dosing schedule for aflibercept…","The proportion of eyes exhibiting fluid — Between 8 - 16 weeks (At the same interval as the previous dosing schedule fo…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41457","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}